An endovascular apparatus including a stabilizing element and a rod that may be detachably coupled to the stabilizing element. The rod may be elongated along a longitudinal axis. The rod may have at least one therapeutic agent thereon. The therapeutic agent may be an enzyme, an antibody, a biomarker, or a bioreceptor for neutralizing components of a bodily fluid of a patient. The rod may be inserted into the patient's body to place the therapeutic agent into fluid communication with the patient's bodily fluid. The rod may be formed from silicone and an outer surface of the rod may be etched prior to coating the rod with the therapeutic agent.

An object of the present invention is to provide a material which can remove an activated leukocyte-activated platelet complex with high efficiency. The present invention provides a material for removing an activated leukocyte-activated platelet complex, the material being a water-insoluble carrier to the surface of which carrier a compound(s) having a charged functional group(s) is(are) bound, wherein an extending length ratio of the surface is 4 to 7.

Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may include a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector may define a sterile fluid flowpath between the container and the insertion mechanism. Optionally, a cannula initially disposed about the needle may be included. The cannula may be retained in the patient at an injection site created by the needle after the needle is withdrawn from the patient. Methods of assembly and operation are also provided.

Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device includes a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector defines a sterile fluid flowpath between the container and the insertion mechanism. A cannula initially disposed about the needle is included.

An object of the present invention is to provide a material which can remove an activated leukocyte-activated platelet complex with high efficiency. The present invention provides a material for removing an activated leukocyte-activated platelet complex, the material being a water-insoluble carrier to the surface of which carrier a compound(s) having a charged functional group(s) is(are) bound, wherein an extending length ratio of the surface is 4 to 7.

An object of the present invention is to provide a material which can remove an activated leukocyte-activated platelet complex with high efficiency. The present invention provides a material for removing an activated leukocyte-activated platelet complex, the material being a water-insoluble carrier to the surface of which carrier a compound(s) having a charged functional group(s) is(are) bound, wherein an extending length ratio of the surface is 4 to 7.

A whole blood treatment device includes a first conduit, a second conduit, and a rotating or reciprocating element having a channel. The first and second conduits are fluidly coupled to the rotating or reciprocating element such that the channel is fluidly continuous with the first conduit when the channel is fluidly discontinuous with the second conduit, and such that the channel is fluidly discontinuous with the first conduit when the channel is fluidly continuous with the second conduit. The first conduit is configured to receive whole blood, and the second conduit is configured to receive a regeneration fluid. The channel comprises a surface that is modified with an affinity agent at a concentration effective to allow removal of a target compound from whole blood.

Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device includes a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector defines a sterile fluid flowpath between the container and the insertion mechanism. A cannula initially disposed about the needle is included.

A whole blood treatment device includes a first conduit, a second conduit, and a rotating or reciprocating element having a channel. The first and second conduits are fluidly coupled to the rotating or reciprocating element such that the channel is fluidly continuous with the first conduit when the channel is fluidly discontinuous with the second conduit, and such that the channel is fluidly discontinuous with the first conduit when the channel is fluidly continuous with the second conduit. The first conduit is configured to receive whole blood, and the second conduit is configured to receive a regeneration fluid. The channel comprises a surface that is modified with an affinity agent at a concentration effective to allow removal of a target compound from whole blood.

An object of the present invention is to provide a material which can remove an activated leukocyte-activated platelet complex with high efficiency. The present invention provides a material for removing an activated leukocyte-activated platelet complex, the material being a water-insoluble carrier to the surface of which carrier a compound(s) having a charged functional group(s) is(are) bound, wherein an extending length ratio of the surface is 4 to 7.